A jury says Boston Scientific Corp. must pay $431 million in damages in a patent dispute over the medical device maker’s drug-coated stents.
The company said that federal jury in Marshall, Texas reached the damages award in a patent infringement lawsuit brought by Dr. Bruce Saffran. The jury found that Boston Scientific’s Taxus Express and Taxus Liberte stents infringe on a patent that Saffran holds.
Boston Scientific argues the verdict is unsupported by evidence and the law. The Natick, Massachusetts-based company plans to try to overturn the verdict in post-trial motions. If that’s unsuccessful, Boston Scientific says it will appeal.
Stents are tiny, mesh-wire tubes that prop open arteries after they have been surgically cleared of fatty plaque.
Topics Massachusetts
Was this article valuable?
Here are more articles you may enjoy.
Florida Insurance Costs 14.5% Lower Than Without Reforms, Report Finds 
Trump Demands $1 Billion From Harvard as Prolonged Standoff Appears to Deepen 
AIG Underwriting Income Up 48% in Q4 on North America Commercial 
BMW Recalls Hundreds of Thousands of Cars Over Fire Risk 
